Journals / Dicle Tıp Dergisi / 2016 / Cilt: 43 Sayı: 1

Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Pages
—
Publication Date
2016-03-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor.
📊
Key Findings & Data:One should be aware of serious complications even though bevacizumab is a well-tolerated drug.
💡
Conclusion & Impact:Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Bevacizumab · ince barsak perforasyonu · metastatik kolorektal kanser

Özet

Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery. Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer

🔖

Cite This Article

Çetin, D., Gündeş, E., Aday, U., Çiyiltepe, H., Değer, K., Duman, M. (2016). Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Tıp Dergisi, Cilt: 43 Sayı: 1. https://doi.org/10.5798/diclemedj.0921.2016.01.0661

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779- 1802.
  2. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006;4:808-821.
  3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
  4. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354-3360.
  5. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
  6. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab.
  7. Am J Health Syst Pharm 2009; 66:999-1013.
  8. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-869.
  9. Badgwell BD, Camp ER, Feig B, et al. Management of evacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-582.
  10. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180.
  11. Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008;40:33-35.